Openly accessible

Cinobufacini injection for moderate and advanced primary liver cancer: A systematic review and meta-analysis

Dong, Zhiyong, Qiu, Xiantu, Kujawa, Stacy A., Shariful Islam, S.M. and Zhang, Jie 2019, Cinobufacini injection for moderate and advanced primary liver cancer: A systematic review and meta-analysis, Journal of Chinese Pharmaceutical Sciences, vol. 28, no. 4, pp. 264-275, doi: 10.5246/JCPS.2019.04.027.

Attached Files
Name Description MIMEType Size Downloads

Title Cinobufacini injection for moderate and advanced primary liver cancer: A systematic review and meta-analysis
Author(s) Dong, Zhiyong
Qiu, Xiantu
Kujawa, Stacy A.
Shariful Islam, S.M.ORCID iD for Shariful Islam, S.M. orcid.org/0000-0001-7926-9368
Zhang, Jie
Journal name Journal of Chinese Pharmaceutical Sciences
Volume number 28
Issue number 4
Start page 264
End page 275
Total pages 12
Publisher Peking University
Place of publication Beijing, China
Publication date 2019-04
ISSN 1003-1057
Keyword(s) meta-analysis
cancer
systematic review
medicine
Summary Cinobufacini, a compound extracted from bufo toad, is a traditional Chinese medicine (TCM) that has been shown to have efficacy in cancer treatment. The cinobufacini injection is widely used in patients with moderate and advanced liver cancer in China. In the present study, we aimed to determine the effects of cinobufacini injection for this specific category of patients. A search for randomized control trials (RCTs) using cinobufacini was conducted in the PubMed, EMBASE, CENTRAL, and the other four major Chinese databases. The systematic review was performed according to the recommendations of the Cochrane collaboration, and the RevMan 5.3. software was used for statistical analysis. A random-effects model was used to perform the data. Risk ratios (RR) with corresponding 95% confidence interval were calculated according to Cochrane handbook. A total of 11 RCTs consisting of 728 patients were included. All of the trials demonstrated significantly improved total response rates, total response rates of Karnofsky Performance Score (KPS), 1- to 2-year survival rates, and quality of life in the intervention groups injected with cinobufacini. There was no statistically significant difference between the groups (cinobufacini versus no cinobufacini; cinobufacini plus transcatheter arterial chemoembolization (TACE) versus TACE only) in terms of the 6-month survival rate, clinical benefit rate and clinical benefit rate of KPS. This systematic review demonstrated the beneficial effects of cinobufacini injection in terms of total response rate and the 1- to 2-year survival rate in patients with moderate and advanced liver cancer. The efficacy for the cinobufacini injection group might be better than that of the control group for treatment of moderate and advanced liver cancer. Given that the majority of the trials were of low quality, more high-quality prospective RCTs with strict design in accordance with CONSORT for TCM are needed.
Language eng
DOI 10.5246/JCPS.2019.04.027
Indigenous content off
Field of Research 1115 Pharmacology and Pharmaceutical Sciences
HERDC Research category C1 Refereed article in a scholarly journal
Free to Read? Yes
Persistent URL http://hdl.handle.net/10536/DRO/DU:30130449

Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 65 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Thu, 03 Oct 2019, 08:55:12 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.